Shandong Zhanhua Yonghao pharmaceutical & Tech Co.,Ltd

Don't be afraid, AIDS not only has long-term prevention drugs, but also emergency blocking drugs, which are often called PrEP and PEP. Tenofovir was the first nucleotide analogue approved for the treatment of HIV-1 infection. Diethyl p-toluene sulfonyloxy methyl phosphonate(DESMP) plays an important role in the treatment of AIDS.

As the first nucleotide analogue to be approved by the FDA for the treatment of HIV-I infection, tenofovir's importance has been recognized by the World Health Organization and recommended as a first-line antiviral agent. Because of the drug's impact, India in September 2009 accepted a request from Indian generic drug maker Cipla to deny patent protection for tenofovir in order to ensure that the drug would be more accessible to low-income countries.

Tenofovir disoproxil is a drug indicated for the treatment of chronic hepatitis B and for the prevention and treatment of HIV infection/AIDS. The drugs are reverse transcriptase inhibitors, which inhibit the replication of HIV. Tenofovir disoproxil can be used to prevent HIV infection in high-risk individuals, but the drug does not cure HIV/AIDS or hepatitis B.

Many antiviral drugs used alone and in combination can significantly reduce HIV replication and improve patient survival. However, because HIV mutates rapidly and is prone to drug resistance, new drugs need to be constantly developed to suppress drug-resistant virus strains. The FDA approved tenofovir based on the results of two clinical trials involving more than 700 patients. These patients had previously been treated with antiretroviral drugs that did not significantly inhibit HIV replication, and treatment with the drugs for 24 to 48 weeks reduced plasma viral load.

Since tenofovir was approved based on the results of trials in patients who had previously received antiretroviral therapy, the efficacy of tenofovir in first-time patients is uncertain, and more clinical studies are needed to determine whether tenofovir is applicable to first-time patients and children. In addition, there is no data on the long-term clinical efficacy evaluation of the drug.